ArticleBlood advances2018
Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo.
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 55 citations in OpenAlex.
- CAR T cell therapy beyond cancer: current status, challenges and future prospects.Signal transduction and targeted therapy · 2026Review
- Diverse potential of chimeric antigen receptor-engineered cell therapy: Beyond cancer.Clinical and translational medicine · 2025Review
- Depletion of alloreactive B cells by drug-resistant chimeric alloantigen receptor T cells to prevent transplant rejection.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases.Biomarker research · 2025Review
- Current advancements in cellular immunotherapy for autoimmune disease.Seminars in immunopathology · 2025Review
- Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy.Frontiers in immunology · 2025Review
- A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases.Medical oncology (Northwood, London, England) · 2024Review
- Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: AnHeliyon · 2023Article
- Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023.Human vaccines & immunotherapeutics · 2023Review
- Review
- Review
- Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Editorial: Induction of immune tolerance: addressing unmet medical need in immune mediated diseases and immune responses to biologics.Frontiers in immunology · 2023Article
- CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions.Frontiers in ophthalmology · 2023Review
- Therapeutic Opportunities for Immunoreceptor-Engineered T Cell Therapy for Modulation of Alloimmunity.Journal of immunology (Baltimore, Md. : 1950) · 2022Review
- Article
- Article
- Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer.Biomedicines · 2022Review
- Engineered T cells and their therapeutic applications in autoimmune diseases.Zoological research · 2022Review
- CAR-based therapies: opportunities for immuno-medicine beyond cancer.Nature metabolism · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hemophilia A is an X-linked bleeding disorder caused by mutations in the factor VIII (FVIII) gene (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.